Register Login

ONKURE THERAPEUTICS, INC. (OKUR)

SymbolOKUR
NameONKURE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address18575 JAMBOREE ROAD,SUITE 275-S, IRVINE, California, 92612, United States
Telephone+1 619 733-3852
Fax—
Email—
Websitehttps://www.onkuretherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001637715
Description

OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K and has multiple programs designed to enable targeting of this key oncogene.

Additional info from NASDAQ:
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K and has multiple programs designed to enable targeting of this key oncogene.

2026-06-08 22:32

Mathers Edward T 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 262279

Read more
2026-06-08 22:27

Ratcliffe Liam 🟢 acquired 1.3K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000004

Read more
2026-06-08 22:26

Phillips Andrew John 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000002

Read more
2026-06-08 22:25

Jansen Valerie Malyvanh 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000001

Read more
2026-06-08 22:24

GREY MICHAEL G 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000003

Read more
2026-06-08 22:23

Carruthers R Michael 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000001

Read more
2026-06-05 17:16

New Form S-8 - OnKure Therapeutics, Inc. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001193125-26-259599 <b>Size:</b> 478 KB

Read more
2026-05-27 17:37

New Form SCHEDULE 13G - OnKure Therapeutics, Inc. <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0000921895-26-001486 <b>Size:</b> 39 KB

Read more
2026-05-15 21:21

New Form SCHEDULE 13G/A - OnKure Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062876 <b>Size:</b> 13 KB

Read more
2026-05-05 20:10

(19% Negative) ONKURE THERAPEUTICS, INC. (OKUR) Reports Q2 2026 Financial Results

Read more